Company presentation
Logotype for Kimball Electronics Inc

Kimball Electronics (KE) Company presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Kimball Electronics Inc

Company presentation summary

18 May, 2026

Company overview and strategic positioning

  • Global provider of electronics manufacturing and contract manufacturing services, specializing in high-complexity, regulated industries such as automotive, medical, and industrial markets.

  • Operates 7 manufacturing locations across North America, Europe, and Asia, with over 5,500 employees and $1.49B in FY25 revenue.

  • Portfolio rationalization included divesting non-core businesses and integrating medical CMO into core EMS, improving utilization and focus.

  • Emphasizes long-term customer partnerships, with 77% of FY25 revenue from customers with relationships over 10 years.

  • Culture centers on customer focus, people, environmental citizenship, and profit as a measure of efficiency.

Operational capabilities and market focus

  • Offers integrated services across the product lifecycle: design, prototyping, NPI/TOW, manufacturing, testing, and aftermarket support.

  • Specializes in advanced engineering, regulatory compliance (FDA, ISO 9001, ISO 13485), and scientific injection molding for medical devices.

  • Diversified revenue: 49% automotive, 27% medical, 24% industrial in FY25.

  • Automotive growth driven by vehicle electrification and electronic content; medical focus on Class II/III devices and drug delivery; industrial growth in automation and clean energy.

Financial performance and outlook

  • Strong balance sheet with debt down 49% from peak, positive cash from operations for 9 consecutive quarters, and $358.5M in short-term liquidity as of March 2026.

  • Affirmed FY26 guidance: net sales $1.40–$1.46B, adjusted operating income 4.2–4.5% of sales, capex $50–$60M (majority for new Indianapolis facility).

  • Margin expansion expected from better capacity utilization and increased medical business share.

  • Capital allocation prioritizes growth investments, especially in medical CMO, with ongoing share repurchases and potential tuck-in M&A.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more